Trial Profile
Randomized phase II study of daily administrations versus alternate-day administrations of TS-1 in advanced or recurrent gastric cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2015
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 04 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 17 Dec 2012 Planned end date changed from 1 Nov 2013 to 31 Mar 2014 as reporte by University Hospital Medical Information Network - Japan.
- 18 Sep 2012 New trial record